MAP2K4 and leukemia: Studies have reported that SB202190 induces cell death by cross-inhibition of the PI3K-PKB/Akt-mTOR pathway, but not the p38 pathway [38], that SB202190- or SB203580-induced JNK activation is dependent on the MLK-3-MKK4/MKK7-dependent signal transduction pathway [39], and that SB202190 activates ERK1/2 to promote the progression of leukemia [40].